Roche Venture Fund
Corporate VCBasel · Seed–Growth · 6 people tracked
Investment thesis
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
Source: firm website, verified Jul 29, 2026.
Team · 6 people
from the firm's website & public directories
What they invest in
from 21 of 26 portfolio companiesBiotech ×20Healthtech ×14Medical Devices ×8Deep Tech ×3Digital Health ×3AI & Machine Learning ×1Media & Entertainment ×1
HQs:United States×9France×2Denmark×1Spain×1United Kingdom×1Italy×1
Investments · 26 tracked
founders shown can be your intro pathBy year:2021 · 12018 · 12015 · 13 dated
Entrada Therapeutics develops intracellular therapeutics using its EEV Platform to target previously inaccessible disease-causing targets within cells, with a pipeline spanning retinal, neuromuscular, and metabolic diseases including Duchenne muscular dystrophy.
BiotechHealthtechMedical DevicesBoston, US
Natarajan Sethuraman(Executive Officer)Peter Kim(Director)Nerissa Kreher(Executive Officer)Kory Wentworth(Executive Officer)Dipal Doshi(Executive Officer, Director)inJohn F. Crowley(Director)
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon
Riley Ennis(Co-Founder and Chief Product Officer)Stuart Lawson(Director)Charles Roberts(Director)Gabriel Otte(Director)
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.
BiotechDeep TechDigital HealthHealthtechMarseille, FR
Benjamin Charles(Co-Founder & CEO)Patrick Collombat(Co-Founder & Scientific Advisor)Jean-Pascal Tranié(Co-Founder)
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)
BiotechWatertown, US
Markus Goebel(Director)Christopher Viehbacher(Director)Joseph Zakrzewski(Director)Henry Skinner(Director)Mary Szela(Director)Vikas Goyal(Director)
Board seatAnja Harmeier· per SEC Form D · $20M raise · filed Mar 2018
Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH.
BiotechHealthtechSouth San Francisco, US
Hardean Achneck(Executive Officer)Carole Neuchterlein(Director)Peter Moldt(Director)Sushmita Chanda(Executive Vice President - Preclinical Development)Kathleen Glaub(Director)Brian Dowd(Executive Vice President - Controller)
Bonum Therapeutics is an early-stage biotechnology company.
BiotechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)Neela Patel(Executive Officer)Diane Hollenbaugh(Executive Officer)
BoardSamuel Bjork(Director)Monique Schiersing(Director)John McKearn(Director)
COUR develops targeted therapies for autoimmune diseases using an antigen-specific platform technology designed to restore immune tolerance while preserving normal immune function.
BiotechHealthtechMedical Devices
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Jason Coloma(Director)Ann Lee-Karlon(Executive Officer, Director)Samuel Bjork(Director)Alexandra Cantley(Director)Mitchell Mutz(Executive Officer, Director)Seiji Miyahara(Director)
Forcefield Therapeutics develops cardioprotective proteins for the treatment of cardiac disease, with an initial focus on myocardial infarction (heart attack).
BiotechHealthtechMedical Devices
John
BiotechSan Diego, US
Yi Liu(Executive Officer, Director)Lynn Yang(Director)
BoardCarl Gordon(Director)
Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.
BiotechHealthtech
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.
BiotechDeep TechHealthtechMedical DevicesAarhus, DK
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)Volker Knappertz(Executive Vice President of Research & Development)Michael Samar(Chief Financial Officer)Rob Lasser(Chief Medical Officer)
BiotechBrisbane, US
Stephen Brady(Director)Matthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)Thomas Woiwode(Director)Geoffrey Nichol(Director)Thomas W. Dubensky(Executive Officer, Director)
Pharmaceutical-technology.com is a B2B media and news website covering pharma, biotech, medical technology, and health tech, part of GlobalData's network of proprietary industry sites.
HealthtechMedia & EntertainmentLondon, GB
Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions.
BiotechHealthtechCambridge, US
WILLIAM CIAMBRONE(Executive Officer)HANS WIGZELL(Director)CLAUDE NICAISE(Director)DOUGLAS S. INGRAM(Executive Officer, Director)DAVID TYRONNE HOWTON(Executive Officer)MARY ANN GRAY(Director)
Vivet Therapeutics is a company focused on gene and cell therapy development, presenting research at major scientific conferences.
BiotechParis, FR
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
IPOs and acquisitions across the tracked portfolioEnliven TherapeuticsNASDAQ: ELVNEntrada Therapeutics, Inc.NASDAQ: TRDAFreenomeNASDAQ: FRNM
Portfolio news
latest coverage across their companiesMironid · eu-startups.com · Aug 7, 2026
Photo of Tempest Therapeutics · tipranks.com · Jul 22, 2026
Frequently asked questions
- What stage does Roche Venture Fund invest at?
- Roche Venture Fund invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Roche Venture Fund's typical check size?
- Roche Venture Fund typically writes checks of $648K – $3.2M.
- What sectors does Roche Venture Fund focus on?
- Roche Venture Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices, Sector Agnostic.
- Where is Roche Venture Fund located?
- Roche Venture Fund is headquartered in Basel, CH.
Images
Co-investors · 23
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Ysios Capital is a life sciences investor that finances innovative biotech companies worldwide, providing resources to develop novel therapies for indications with high unmet medical needs.
Digitalis Ventures invests in solutions to unmet needs in biomedicine and health, backing biotechnology and technology-enabled companies across human health and animal health.
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
BioGeneration Ventures is a venture capital firm that invests in early-stage biotech companies in Europe, with a focus on healthcare innovations.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Inkef is an early-stage, hands-on investor that helps build companies with a long-term strategic vision, aiming for sustainable returns.
RiverVest Venture Partners is a life sciences venture capital firm that invests in biotechnology and medical companies, working with entrepreneurs to advance therapeutic and medical innovations.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
▶11 more co-investors
Atlas VentureSR One Capital ManagementDeerfield Management CompanyMorgenthalerHatteras Venture PartnersOmega FundsLightstone VenturesApollo Health VenturesFaberWestlake Village BioPartnersCodon Capital
Firms observed investing alongside Roche Venture Fund, from public investor directories. Shared companies are the overlap with Roche Venture Fund's recorded portfolio.
Similar investors
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
Innovestor is a Nordic investment group operating across venture capital, life science, real estate, energy storage, and corporate venturing platforms, and is among the most active early-stage investors in the region.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.